• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

West Virginia wants Justice Dept. to nix Mylan settlement

November 3, 2016 By Sarah Faulkner

West Virginia wants Justice Dept. to nix Mylan settlement(Reuters) – West Virginia Attorney General Patrick Morrisey on Wednesday blasted a pending $465 million settlement between Mylan NV (NSDQ:MYL) and the U.S. Justice Dept. over the misclassification of the EpiPen, saying it was “woefully deficient.”

In a Nov. 2 letter to Attorney General Loretta Lynch, Morrisey said the amount likely fell short of how much the company owed Medicaid, and that Mylan should “not be allowed to receive a windfall after flagrantly defrauding the Medicaid Drug Rebate Program.”

Spokeswomen for the Justice Dept. and Mylan did not immediately respond to requests for comment.

Morrisey’s letter came just a few weeks after Mylan announced a $465 million settlement with the Justice Department over charges it had underpaid U.S. government healthcare programs by misclassifying the EpiPen.

But the Justice Department has not acknowledged such a settlement, and department spokeswoman Nicole Navas declined earlier Wednesday to comment on any pending settlement.

Mylan has come under fire for hiking the price of the lifesaving allergy treatment to more than $600 for a package of two in less than a decade.

For years, the company had classified the allergy treatment as a generic drug instead of a branded one, resulting in smaller rebates to state and federal Medicaid programs.

The Medicaid rebate for a generic is 13% compared with a minimum 23.1% for a branded drug.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Legal News Tagged With: Mylan

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS